CX3CL1 inhibits NLRP3 inflammasome-induced microglial pyroptosis and improves neuronal function in mice with experimentally-induced ischemic stroke
- 21 April 2022
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 300, 120564
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81571138, 82071485)
This publication has 41 references indexed in Scilit:
- Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stageOpen Biology, 2013
- Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic StrokeStroke, 2012
- Delayed Administration of Interleukin-1 Receptor Antagonist Reduces Ischemic Brain Damage and Inflammation in Comorbid RatsJournal of Cerebral Blood Flow & Metabolism, 2012
- CX3CL1 Is Neuroprotective in Permanent Focal Cerebral Ischemia in RodentsJournal of Neuroscience, 2011
- The immunology of stroke: from mechanisms to translationNature Medicine, 2011
- Role of CX3CR1 (Fractalkine Receptor) in Brain Damage and Inflammation Induced by Focal Cerebral Ischemia in MouseJournal of Cerebral Blood Flow & Metabolism, 2008
- Neuronal ‘On’ and ‘Off’ signals control microgliaTrends in Neurosciences, 2007
- Atorvastatin Induction of VEGF and BDNF Promotes Brain Plasticity after Stroke in MiceJournal of Cerebral Blood Flow & Metabolism, 2005
- Fractalkine and fractalkine receptors in human neurons and glial cellsJournal of Neuroscience Research, 2002
- Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injuryJournal of Neuroimmunology, 2002